Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: A clinician's perspective

The introduction of two thrombopoietin-receptor (TPO) agonists (romiplostim and eltrombopag) in the treatment of immune thrombocytopenia (ITP) may represent a major improvement. Registrative [1-4] and extension studies [5, 6] showed that these agents are able to produce a sustained increase of platelet counts, a reduced use of concomitant ITP-specific therapies, and a global reduction of bleeding episodes with a general improvement of the...